Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz
Canan
C
Aydin
G Burca
GB
Cila
Aysenur
A
Akalan
Nejat
N
Soylemezoglu
Figen
F
Cengiz
Mustafa
M
Yazici
Nalan
N
Buyukpamukcu
Munevver
M
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D000069283:Rituximab; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab